Satellos revises DMD trial endpoint after FDA feedback
Satellos Bioscience said on November 6, 2026 that its BASECAMP Phase 2 study will evaluate changes in MRI-derived fat content in the vastus lateralis muscle as its main efficacy measure, replacing dynamometry. The trial is testing oral forazapadin in 53 boys ages 7, 8 or 9 with Duchenne muscular dystrophy, and the company expects results from the initial 12-week placebo-controlled period in Q1 2027. Satellos said the revised measure, alongside clinical outcomes, could contribute to a potential accelerated-approval route.
Why it matters
The endpoint change alters the principal efficacy measure used in BASECAMP and may affect how future results are assessed by the FDA. Satellos expects the revised approach could support a potential accelerated-approval pathway if the study produces supportive results.
Key facts
- 1The protocol amendment replaces dynamometry with MRI-measured change in vastus lateralis fat fraction as BASECAMP's primary efficacy endpoint. stocktitan.net
- 2BASECAMP is enrolling 53 boys ages 7, 8 or 9 with Duchenne muscular dystrophy. investing.com
- 3Satellos expects topline results from the 12-week placebo-controlled period in Q1 2027. investing.com
- 4In the adult TRAILHEAD study, muscle fat fraction declined by a mean 3.7 percentage points, from 49.7% at baseline to 46.0% at Day 140. investing.com
- 5BASECAMP includes a 36-week active-treatment period after its initial 12-week placebo-controlled period. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.